Company Overview - Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is focused on developing and commercializing treatments for skin diseases, with its lead product candidate, VP-102, targeting molluscum contagiosum [1] Financial Performance - VRCA has a Return on Invested Capital (ROIC) of -166.93%, significantly lower than its Weighted Average Cost of Capital (WACC) of 17.69%, indicating inefficiencies in capital utilization [2][6] - The ROIC to WACC ratio for VRCA is -9.44, further emphasizing the challenge in generating sufficient returns to cover its cost of capital [2] Comparative Analysis - Y-mAbs Therapeutics (YMAB) has a ROIC of -27.64% and a WACC of 6.11%, resulting in a ROIC to WACC ratio of -4.53, making it the least inefficient among its peers [3][5] - Scholar Rock Holding Corporation (SRRK) shows a ROIC of -109.48% against a WACC of 5.32%, leading to a ROIC to WACC ratio of -20.57, indicating similar inefficiencies as VRCA [4] - Crinetics Pharmaceuticals (CRNX) and Kezar Life Sciences (KZR) also exhibit negative ROIC to WACC ratios of -6.99 and -10.94, respectively, highlighting broader challenges within the sector [4][5] Sector Insights - All companies analyzed, including VRCA, are currently operating at a loss relative to their cost of capital, with Y-mAbs Therapeutics managing its capital more effectively than its peers [5][6]

Core Viewpoint - UBS reported that Beijing Capital International Airport Co., Ltd. (00694) experienced a 2.6% year-on-year revenue increase to 2.8 billion RMB, with losses narrowing to 163 million RMB compared to a loss of 376 million RMB in the same period last year, although the performance fell short of the bank's and market expectations [1] Financial Performance - Revenue for the first half of the year reached 2.8 billion RMB, reflecting a 2.6% increase year-on-year [1] - Losses decreased to 163 million RMB, an improvement from the previous year's loss of 376 million RMB [1] Earnings Forecast - UBS revised its earnings per share (EPS) forecasts for 2025 to 2027 from 0.02 RMB, 0.08 RMB, and 0.13 RMB to -0.05 RMB, 0 RMB, and 0.04 RMB respectively [1] Target Price Adjustment - The target price was slightly adjusted from 3.1 HKD to 3.22 HKD due to a decrease in the weighted average cost of capital (WACC) [1] - UBS maintains a neutral rating on the stock [1]

Core Viewpoint - UBS reported that Beijing Capital International Airport's revenue for the first half of the year increased by 2.6% year-on-year to 2.8 billion yuan, with losses narrowing to 163 million yuan compared to a loss of 376 million yuan in the same period last year, although the performance fell short of the bank's and market expectations [1] Financial Performance - Revenue for the first half of the year reached 2.8 billion yuan, reflecting a year-on-year growth of 2.6% [1] - Losses decreased to 163 million yuan, an improvement from the previous year's loss of 376 million yuan [1] Earnings Forecast - The earnings per share (EPS) forecasts for 2025 to 2027 were revised down from 0.02 yuan, 0.08 yuan, and 0.13 yuan to -0.05 yuan, 0 yuan, and 0.04 yuan respectively [1] Target Price Adjustment - The target price was slightly adjusted from 3.1 HKD to 3.22 HKD due to a reduction in the weighted average cost of capital (WACC) [1] - The rating was maintained at "Neutral" [1]